Gary J Schiller

Title(s)Professor-in-Residence, Medicine
SchoolMedicine
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition With Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild Type Acute Myeloid Leukemias. Clin Cancer Res. 2025 May 06. Zhang W, Li L, Muftuoglu M, Basyal M, Togashi N, Iwanaga K, Tanzawa F, Numata M, Bixby DL, Erba HP, Podoltsev N, Schiller GJ, Kumar P, Lesegretain A, Isoyama T, Seki T, Daver N, Andreeff M. PMID: 40327322.
      View in: PubMed   Mentions:    Fields:    
    2. Omidubicel-onlv Transplantation for Hematologic Malignancies: Results of a Multicenter Expanded Access Program. Transplant Cell Ther. 2025 Apr 08. Horwitz ME, Schiller GJ, Tsai SB, Rezvani AR, Maziarz RT, Goshen U, Levy S, Schwarzbach A, Mazor RD, Stiff PJ. PMID: 40204073.
      View in: PubMed   Mentions:    Fields:    
    3. Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial. Blood Cancer J. 2025 Apr 03; 15(1):55. Hoff FW, Huang Y, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Patel PA, Collins RH, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike O, Redner RL, Kovacsovics T, Deininger MW, Zeidner JF, Olin RL, Smith CC, Foran JM, Schiller GJ, Curran EK, Koenig KL, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate UM, Mims AS, Byrd JC, Madanat YF. PMID: 40180903; PMCID: PMC11968959.
      View in: PubMed   Mentions:    Fields:    
    4. Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. Leukemia. 2025 May; 39(5):1058-1068. Shah BD, Cassaday RD, Park JH, Houot R, Logan AC, Boissel N, Leguay T, Bishop MR, Topp MS, O'Dwyer KM, Tzachanis D, Arellano ML, Lin Y, Baer MR, Schiller GJ, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Mao D, Adhikary S, Zhou L, Hadjivassileva T, Damico Khalid R, Ghobadi A, Oluwole OO. PMID: 40108332; PMCID: PMC12055586.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial. J Hematol Oncol. 2025 Jan 16; 18(1):7. Cortes JE, Roboz GJ, Baer MR, Jonas BA, Schiller GJ, Yee K, Ferrell PB, Yang J, Wang ES, Blum WG, Mims A, Tian H, Sheppard A, de Botton S, Montesinos P, Curti A, Watts JM, Olutasidenib Combination Therapy Study Group. PMID: 39819505; PMCID: PMC11736922.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    6. Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm. Br J Haematol. 2025 Apr; 206(4):1121-1128. De Botton S, Récher C, Cortes J, Curti A, Fenaux P, Peterlin P, Pigneux A, Yee K, Wei A, Mims A, Schiller G, Chao MM, Tian H, Watts JM. PMID: 39701584; PMCID: PMC11985372.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    7. CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial. Leuk Lymphoma. 2025 Apr; 66(4):773-779. Oliai C, Park S, Damon LE, Jonas BA, Jeyakumar D, Wieduwilt MJ, Logan AC, Callas B, Hannigan CA, Gaut DL, Schiller GJ. PMID: 39689718.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    8. Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy. Blood Adv. 2024 10 22; 8(20):5297-5305. Hoff FW, Blum WG, Huang Y, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Archer KJ, Patel PA, Collins RH, Baer MR, Duong VH, Arellano ML, Stock W, Odenike O, Redner RL, Kovacsovics T, Deininger MW, Zeidner JF, Olin RL, Smith CC, Foran JM, Schiller GJ, Curran EK, Koenig KL, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate UM, Mims AS, Byrd JC, Madanat YF. PMID: 39110987; PMCID: PMC11497398.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    9. Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial. Lancet Oncol. 2024 Oct; 25(10):1310-1324. Wang ES, Issa GC, Erba HP, Altman JK, Montesinos P, DeBotton S, Walter RB, Pettit K, Savona MR, Shah MV, Kremyanskaya M, Baer MR, Foran JM, Schiller G, Adès L, Heiblig M, Berthon C, Peterlin P, Rodríguez-Arbolí E, Salamero O, Patnaik MM, Papayannidis C, Grembecka J, Cierpicki T, Clegg B, Ray J, Linhares BM, Nie K, Mitra A, Ahsan JM, Tabachri M, Soifer HS, Corum D, Leoni M, Dale S, Fathi AT. PMID: 39362248.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    10. Risk Factors and Outcomes of Mucorales Infection in a Modern Cohort of Solid Organ Transplant, Hematopoietic Cell Transplant, and Chimeric Antigen Receptor T-cell Therapy Recipients. Transplant Proc. 2024 Sep; 56(7):1683-1690. Ogawa L, Multani A, Beaird OE, Gaynor P, Carlson M, Garner OB, Schiller G, Schaenman JM. PMID: 39174391.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    11. Good Outcomes in Therapy of Fusariosis Depend on Both an Effective Drug and the Host. Clin Infect Dis. 2024 08 16; 79(2):572. Winston DJ, Young PA, Schlamm HT, Schiller GJ. PMID: 38174352.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014. Clin Lymphoma Myeloma Leuk. 2024 Dec; 24(12):852-862. Bahlis NJ, Samaras C, Reece D, Sebag M, Matous J, Berdeja JG, Shustik J, Schiller GJ, Ganguly S, Song K, Seet CS, Acosta-Rivera M, Bar M, Quick D, Fonseca G, Liu H, Gentili C, Singh P, Siegel D. PMID: 39237427.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    13. A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia. Blood Adv. 2024 05 28; 8(10):2527-2535. Levis M, Perl A, Schiller G, Fathi AT, Roboz G, Wang ES, Altman J, Rajkhowa T, Ando M, Suzuki T, Subach RA, Maier G, Madden T, Johansen M, Cheung K, Kurman M, Smith C. PMID: 38502195; PMCID: PMC11131057.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    14. Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Front Oncol. 2024; 14:1352281. White D, Schiller GJ, Madan S, Lentzsch S, Chubar E, Lavi N, Van Domelen DR, Bentur OS, Baljevic M. PMID: 38826786; PMCID: PMC11140414.
      View in: PubMed   Mentions: 1  
    15. Acute pulmonary injury in hematology patients supported with pathogen-reduced and conventional platelet components. Blood Adv. 2024 05 14; 8(9):2290-2299. Wheeler AP, Snyder EL, Refaai M, Cohn CS, Poisson J, Fontaine M, Sehl M, Nooka AK, Uhl L, Spinella PC, Fenelus M, Liles D, Coyle T, Becker J, Jeng M, Gehrie EA, Spencer BR, Young P, Johnson A, O'Brien JJ, Schiller GJ, Roback JD, Malynn E, Jackups R, Avecilla ST, Liu K, Bentow S, Varrone J, Benjamin RJ, Corash LM. PMID: 38447116; PMCID: PMC11116994.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    16. ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study. Target Oncol. 2024 May; 19(3):321-332. Maris M, Salles G, Kim WS, Kim TM, Lyons RM, Arellano M, Karmali R, Schiller G, Cull E, Abboud CN, Batlevi C, Kagiampakis I, Rebelatto MC, Lee Y, Kirby LC, Wang F, Bothos J, Townsley DM, Fathi AT, Ribrag V. PMID: 38683495; PMCID: PMC11111564.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    17. Effectiveness of Single-Fraction, Low-Dose, Bilateral Whole Lung Radiation Therapy for Diffuse Alveolar Hemorrhage Secondary to Extramedullary Hematopoiesis: A Case Report and Review of the Literature. Adv Radiat Oncol. 2024 Jul; 9(7):101506. Neilsen BK, Sleightholm RL, Gower A, Tsai SC, Schiller GJ, Oliai C, Lee A, Raldow A, Tenn S, Venkat PS. PMID: 38799111; PMCID: PMC11127181.
      View in: PubMed   Mentions:
    18. Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML). Leuk Lymphoma. 2024 Aug; 65(8):1145-1152. Cortes J, Jonas BA, Schiller G, Mims A, Roboz GJ, Wei AH, Montesinos P, Ferrell PB, Yee KW, Fenaux P, Schwarer A, Watts JM. PMID: 38538632.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    19. Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results. Blood Adv. 2024 03 26; 8(6):1515-1528. Yacoub A, Borate U, Rampal RK, Ali H, Wang ES, Gerds AT, Hobbs G, Kremyanskaya M, Winton E, O'Connell C, Goel S, Oh ST, Schiller G, McCloskey J, Palmer J, Holmes H, Hager S, Assad A, Erickson-Viitanen S, Zhou F, Daver N. PMID: 38290135; PMCID: PMC10966172.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    20. Inhibition of Ephrin B2 Reverse Signaling Abolishes Multiple Myeloma Pathogenesis. Cancer Res. 2024 Mar 15; 84(6):919-934. Sasine JP, Kozlova NY, Valicente L, Dukov J, Tran DH, Himburg HA, Kumar S, Khorsandi S, Chan A, Grohe S, Li M, Kan J, Sehl ME, Schiller GJ, Reinhardt B, Singh BK, Ho R, Yue P, Pasquale EB, Chute JP. PMID: 38231476; PMCID: PMC10940855.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    21. Considerations regarding maintenance therapy for acute myeloid leukemia in remission. Expert Rev Anticancer Ther. 2024 Jan-Feb; 24(1-2):15-20. Schiller GJ, Kustanovich V. PMID: 38230741.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    22. A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML. Blood Adv. 2024 01 23; 8(2):429-440. Cai SF, Huang Y, Lance JR, Mao HC, Dunbar AJ, McNulty SN, Druley T, Li Y, Baer MR, Stock W, Kovacsovics T, Blum WG, Schiller GJ, Olin RL, Foran JM, Litzow M, Lin T, Patel P, Foster MC, Boyiadzis M, Collins RH, Chervin J, Shoben A, Vergilio JA, Heerema NA, Rosenberg L, Chen TL, Yocum AO, Druggan F, Marcus S, Stefanos M, Druker BJ, Mims AS, Borate U, Burd A, Byrd JC, Levine RL, Stein EM. PMID: 37871309; PMCID: PMC10827405.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    23. Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia. Leuk Lymphoma. 2024 Jan; 65(1):69-77. Gaut D, Oliai C, Boiarsky J, Zhang S, Salhotra A, Azenkot T, Kennedy VE, Khanna V, Olmedo Gutierrez K, Shukla N, Moskoff B, Park G, Afkhami M, Patel A, Jeyakumar D, Mannis G, Logan AC, Jonas BA, Schiller G. PMID: 37801340.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    24. Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories. Blood Adv. 2023 10 24; 7(20):6048-6054. Borate U, Yang F, Press R, Ruppert AS, Jones D, Caruthers S, Zhao W, Vergilio JA, Pavlick DC, Juckett L, Norris B, Bucy T, Burd A, Stein EM, Patel P, Baer MR, Stock W, Schiller G, Blum W, Kovacsovics T, Litzow M, Foran J, Heerema NA, Rosenberg L, Marcus S, Yocum A, Stefanos M, Druker B, Byrd JC, Levine RL, Mims A. PMID: 37459200; PMCID: PMC10582272.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    25. Fosmanogepix Therapy of Disseminated Fusarium Infection. Clin Infect Dis. 2023 09 18; 77(6):848-850. Winston DJ, Young PA, Schlamm HT, Schiller GJ. PMID: 37220752.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    26. Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. J Immunother Cancer. 2023 08; 11(8). Shah BD, Cassaday RD, Park JH, Houot R, Oluwole OO, Logan AC, Boissel N, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff PJ, Jeyakumar D, Mao D, Adhikary S, Zhou L, Schuberth PC, Damico Khalid R, Ghobadia A. PMID: 37648261; PMCID: PMC10471850.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    27. Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML. J Clin Oncol. 2023 09 10; 41(26):4236-4246. Pratz KW, Cherry M, Altman JK, Cooper BW, Podoltsev NA, Cruz JC, Lin TL, Schiller GJ, Jurcic JG, Asch A, Wu R, Hill JE, Gill SC, James AJ, Rich ES, Hasabou N, Perl AE, Levis MJ. PMID: 37379495.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    28. Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. Blood Adv. 2023 06 13; 7(11):2360-2363. Saliba AN, Kaufmann SH, Stein EM, Patel PA, Baer MR, Stock W, Deininger M, Blum W, Schiller GJ, Olin RL, Litzow MR, Lin TL, Ball BJ, Boyiadzis MM, Traer E, Odenike O, Arellano ML, Walker A, Duong VH, Kovacsovics T, Collins RH, Shoben AB, Heerema NA, Foster MC, Peterson KL, Schneider PA, Martycz M, Gana TJ, Rosenberg L, Marcus S, Yocum AO, Chen T, Stefanos M, Mims AS, Borate U, Burd A, Druker BJ, Levine RL, Byrd JC, Foran JM. PMID: 36315007; PMCID: PMC10230164.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    29. Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies. Clin Lymphoma Myeloma Leuk. 2023 09; 23(9):e286-e296.e4. Schiller GJ, Lipe BC, Bahlis NJ, Tuchman SA, Bensinger WI, Sutherland HJ, Lentzsch S, Baljevic M, White D, Kotb R, Chen CI, Rossi A, Biran N, LeBlanc R, Grosicki S, Martelli M, Gunsilius E, Špicka I, Stevens DA, Facon T, Mesa MG, Zhang C, Van Domelen DR, Bentur OS, Gasparetto C. PMID: 37393120.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    30. Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial. Cancer. 2023 08 01; 129(15):2308-2320. Duong VH, Ruppert AS, Mims AS, Borate U, Stein EM, Baer MR, Stock W, Kovacsovics T, Blum W, Arellano ML, Schiller GJ, Olin RL, Foran JM, Litzow MR, Lin TL, Patel PA, Foster MC, Redner RL, Al-Mansour Z, Cogle CR, Swords RT, Collins RH, Vergilio JA, Heerema NA, Rosenberg L, Yocum AO, Marcus S, Chen T, Druggan F, Stefanos M, Gana TJ, Shoben AB, Druker BJ, Burd A, Byrd JC, Levine RL, Boyiadzis MM. PMID: 37078412; PMCID: PMC11225573.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    31. CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. Cancer Discov. 2023 03 01; 13(3):580-597. Larson SM, Walthers CM, Ji B, Ghafouri SN, Naparstek J, Trent J, Chen JM, Roshandell M, Harris C, Khericha M, Schweppe T, Berent-Maoz B, Gosliner SB, Almaktari A, Ceja MA, Allen-Auerbach MS, Said J, Nawaly K, Mead M, de Vos S, Young PA, Oliai C, Schiller GJ, Timmerman JM, Ribas A, Chen YY. PMID: 36416874; PMCID: PMC9992104.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    32. Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials. Transplant Cell Ther. 2023 May; 29(5):338.e1-338.e6. Lin C, Schwarzbach A, Sanz J, Montesinos P, Stiff P, Parikh S, Brunstein C, Cutler C, Lindemans CA, Hanna R, Koh LP, Jagasia MH, Valcarcel D, Maziarz RT, Keating AK, Hwang WYK, Rezvani AR, Karras NA, Fernandes JF, Rocha V, Badell I, Ram R, Schiller GJ, Volodin L, Walters MC, Hamerschlak N, Cilloni D, Frankfurt O, McGuirk JP, Kurtzberg J, Sanz G, Simantov R, Horwitz ME. PMID: 36775201; PMCID: PMC10149622.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    33. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. Blood. 2023 02 09; 141(6):567-578. Pemmaraju N, Kantarjian H, Sweet K, Wang E, Senapati J, Wilson NR, Konopleva M, Frankel AE, Gupta V, Mesa R, Ulrickson M, Gorak E, Bhatia S, Budak-Alpdogan T, Mason J, Garcia-Romero MT, Lopez-Santiago N, Cesarman-Maus G, Vachhani P, Lee S, Bhatt VR, Blum W, Walter RB, Bixby D, Gojo I, Duvic M, Rampal RK, de Lima M, Foran J, Fathi AT, Hall AC, Jacoby MA, Lancet J, Mannis G, Stein AS, Mims A, Rizzieri D, Olin R, Perl A, Schiller G, Shami P, Stone RM, Strickland S, Wieduwilt MJ, Daver N, Ravandi F, Vasu S, Guzman M, Roboz GJ, Khoury J, Qazilbash M, Aung PP, Cuglievan B, Madanat Y, Kharfan-Dabaja MA, Pawlowska A, Taylor J, Tallman M, Dhakal P, Lane AA. PMID: 36399715.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    34. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy. Transplant Cell Ther. 2023 04; 29(4):265.e1-265.e10. Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, Schiller GJ, Martinelli G, Neubauer A, Sierra J, Montesinos P, Recher C, Yoon SS, Maeda Y, Hosono N, Onozawa M, Kato T, Kim HJ, Hasabou N, Nuthethi R, Tiu R, Levis MJ. PMID: 36526260; PMCID: PMC10189888.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    35. Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study. J Hematol Oncol. 2022 12 10; 15(1):170. Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Park JH, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Dong J, Adhikary S, Zhou L, Schuberth PC, Faghmous I, Masouleh BK, Houot R. PMID: 36494725; PMCID: PMC9734710.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    36. Adapting the HCT-CI Definitions for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2023 02; 29(2):123.e1-123.e10. Friend BD, Broglie L, Logan BR, Chhabra S, Bupp C, Schiller G, Beitinjaneh A, Perez MAD, Guilcher GMT, Hashem H, Hildebrandt GC, Krem MM, Lazarus HM, Nishihori T, Nusrat R, Rotz SJ, Wirk B, Wieduwilt M, Pasquini M, Savani BN, Stadtmauer EA, Sorror ML, Thakar MS. PMID: 36442769; PMCID: PMC9911376.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    37. Expanded HCT-CI Definitions Capture Comorbidity Better for Younger Patients of Allogeneic HCT for Nonmalignant Diseases. Transplant Cell Ther. 2023 02; 29(2):125.e1-125.e9. Broglie L, Friend BD, Chhabra S, Logan BR, Bupp C, Schiller G, Savani BN, Stadtmauer E, Abraham AA, Aljurf M, Badawy SM, Perez MAD, Guinan EC, Hashem H, Krem MM, Lazarus HM, Rotz SJ, Wirk B, Yared JA, Pasquini M, Thakar MS, Sorror ML. PMID: 36442768; PMCID: PMC9911359.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    38. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. Lancet Haematol. 2023 Jan; 10(1):e46-e58. Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, Dinner SN, Pigneux A, Montesinos P, Wang ES, Seiter KP, Wei AH, De Botton S, Arnan M, Donnellan W, Schwarer AP, Récher C, Jonas BA, Ferrell PB, Marzac C, Kelly P, Sweeney J, Forsyth S, Guichard SM, Brevard J, Henrick P, Mohamed H, Cortes JE. PMID: 36370742.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    39. Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment. EJHaem. 2022 Nov; 3(4):1270-1276. Baljevic M, Gasparetto C, Schiller GJ, Tuchman SA, Callander NS, Lentzsch S, Monge J, Kotb R, Bahlis NJ, White D, Chen CI, Sutherland HJ, Madan S, LeBlanc R, Sebag M, Venner CP, Bensinger WI, Biran N, DeCastro A, Van Domelen DR, Zhang C, Shah JJ, Shacham S, Kauffman MG, Bentur OS, Lipe B. PMID: 36467792; PMCID: PMC9713049.
      View in: PubMed   Mentions: 8  
    40. How thinly can one slice the AML diagnostic pie? Blood. 2022 09 22; 140(12):1330-1331. Schiller G. PMID: 36136361.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    41. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. J Clin Oncol. 2022 12 10; 40(35):4048-4059. Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, McCloskey J, Smith CC, Schiller G, Bradley T, Tiu RV, Naqvi K, Dail M, Brackman D, Siddani S, Wang J, Chyla B, Lee P, Altman JK. PMID: 35849791; PMCID: PMC9746764.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansCTClinical Trials
    42. Comparative risk of pulmonary adverse events with transfusion of pathogen reduced and conventional platelet components. Transfusion. 2022 07; 62(7):1365-1376. Snyder EL, Wheeler AP, Refaai M, Cohn CS, Poisson J, Fontaine M, Sehl M, Nooka AK, Uhl L, Spinella P, Fenelus M, Liles D, Coyle T, Becker J, Jeng M, Gehrie EA, Spencer BR, Young P, Johnson A, O'Brien JJ, Schiller GJ, Roback JD, Malynn E, Jackups R, Avecilla ST, Lin JS, Liu K, Bentow S, Peng HL, Varrone J, Benjamin RJ, Corash LM. PMID: 35748490; PMCID: PMC9544211.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    43. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood. 2022 06 09; 139(23):3366-3375. Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, Schiller GJ, Martinelli G, Neubauer A, Sierra J, Montesinos P, Récher C, Yoon SS, Hosono N, Onozawa M, Chiba S, Kim HJ, Hasabou N, Lu Q, Tiu R, Levis MJ. PMID: 35081255; PMCID: PMC9197557.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    44. Differential use of the hematopoietic cell transplantation-comorbidity index among adult and pediatric transplant physicians. Leuk Lymphoma. 2022 10; 63(10):2507-2510. Broglie L, Friend BD, Chhabra S, Bupp C, Schiller GJ, Logan B, Pasquini MC, Savani B, Stadtmauer EA, Thakar MS, Sorror M. PMID: 35583292; PMCID: PMC9875328.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    45. Diminished durability of chimeric antigen receptor T-cell efficacy with severe or prolonged postinfusion cytopenias. Am J Hematol. 2022 07; 97(7):E249-E255. Tabbara N, Sharp J, Gaut D, Pham TTD, Tang K, Oliai C, Sim MS, Schiller G, Young P, Sasine JP. PMID: 35358346.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    46. Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial. Leuk Lymphoma. 2022 06; 63(6):1407-1417. Bahlis NJ, Siegel DS, Schiller GJ, Samaras C, Sebag M, Berdeja J, Ganguly S, Matous J, Song K, Seet CS, Acosta-Rivera M, Bar M, Quick D, Anz B, Fonseca G, Chung W, Lee K, Mouro J, Agarwal A, Reece D. PMID: 35133221.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    47. Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients. Br J Cancer. 2022 03; 126(5):718-725. Gasparetto C, Schiller GJ, Tuchman SA, Callander NS, Baljevic M, Lentzsch S, Rossi AC, Kotb R, White D, Bahlis NJ, Chen CI, Sutherland HJ, Madan S, LeBlanc R, Sebag M, Venner CP, Bensinger WI, Biran N, Ammu S, Ben-Shahar O, DeCastro A, Van Domelen D, Zhou T, Zhang C, Bentur OS, Shah J, Shacham S, Kauffman M, Lipe B. PMID: 34802051; PMCID: PMC8605887.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    48. Immunotherapy for Acute Myeloid Leukemia: Allogeneic hematopoietic cell transplantation is here to stay. Leuk Res. 2022 01; 112:106732. Kaleka G, Schiller G. PMID: 34864447.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    49. Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. Blood. 2021 10 21; 138(16):1429-1440. Horwitz ME, Stiff PJ, Cutler C, Brunstein C, Hanna R, Maziarz RT, Rezvani AR, Karris NA, McGuirk J, Valcarcel D, Schiller GJ, Lindemans CA, Hwang WYK, Koh LP, Keating A, Khaled Y, Hamerschlak N, Frankfurt O, Peled T, Segalovich I, Blackwell B, Wease S, Freedman LS, Galamidi-Cohen E, Sanz G. PMID: 34157093; PMCID: PMC9710469.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    50. Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. BMC Cancer. 2021 Sep 06; 21(1):993. Tremblay G, Daniele P, Breeze J, Li L, Shah J, Shacham S, Kauffman M, Engelhardt M, Chari A, Nooka A, Vogl D, Gavriatopoulou M, Dimopoulos MA, Richardson P, Biran N, Siegel D, Vlummens P, Doyen C, Facon T, Mohty M, Meuleman N, Levy M, Costa L, Hoffman JE, Delforge M, Kaminetzky D, Weisel K, Raab M, Dingli D, Tuchman S, Laurent F, Vij R, Schiller G, Moreau P, Richter J, Schreder M, Podar K, Parker T, Cornell RF, Lionel K, Choquet S, Sundar J. PMID: 34488662; PMCID: PMC8419947.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    51. Beyond steroids: A systematic review and proposed solutions to managing acute graft-versus-host disease in adolescents and young adults. Blood Rev. 2022 03; 52:100886. Friend BD, Schiller GJ. PMID: 34509319.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    52. Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). Cancer. 2021 12 01; 127(23):4421-4431. Kantarjian HM, Begna KH, Altman JK, Goldberg SL, Sekeres MA, Strickland SA, Arellano ML, Claxton DF, Baer MR, Gautier M, Berman E, Seiter K, Solomon SR, Schiller GJ, Luger SM, Butrym A, Gaidano G, Thomas XG, Montesinos P, Rizzieri DA, Quick DP, Venugopal P, Gaur R, Maness LJ, Kadia TM, Ravandi F, Buyse ME, Chiao JH. PMID: 34424530; PMCID: PMC9523989.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    53. A slow-go prognosis for older patients with newly diagnosed AML. Blood. 2021 08 19; 138(7):501-502. Schiller G. PMID: 34410354.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    54. Vaccine-Associated Measles in a Hematopoietic Cell Transplant Recipient: Case Report and Comprehensive Review of the Literature. Open Forum Infect Dis. 2021 Aug; 8(8):ofab326. Chang SY, Bisht A, Faysman K, Schiller GJ, Uslan DZ, Multani A. PMID: 34377725; PMCID: PMC8339276.
      View in: PubMed   Mentions: 4  
    55. Real-World Experience of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Aggressive B-cell Lymphomas: A Single-Institution Experience. Clin Lymphoma Myeloma Leuk. 2021 12; 21(12):861-872. Ghafouri S, Fenerty K, Schiller G, de Vos S, Eradat H, Timmerman J, Larson S, Mead M. PMID: 34389271.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    56. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood. 2021 07 08; 138(1):11-22. Shah BD, Bishop MR, Oluwole OO, Logan AC, Baer MR, Donnellan WB, O'Dwyer KM, Holmes H, Arellano ML, Ghobadi A, Pagel JM, Lin Y, Cassaday RD, Park JH, Abedi M, Castro JE, DeAngelo DJ, Malone AK, Mawad R, Schiller GJ, Rossi JM, Bot A, Shen T, Goyal L, Jain RK, Vezan R, Wierda WG. PMID: 33827116; PMCID: PMC9999039.
      View in: PubMed   Mentions: 83     Fields:    Translation:HumansCTClinical Trials
    57. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021 Jul; 8(7):e481-e491. Lancet JE, Uy GL, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Faderl S, Cortes JE. PMID: 34171279.
      View in: PubMed   Mentions: 72     Fields:    Translation:HumansCTClinical Trials
    58. Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia. J Clin Oncol. 2021 10 10; 39(29):3261-3272. Desai PM, Brown J, Gill S, Solh MM, Akard LP, Hsu JW, Ustun C, Andreadis C, Frankfurt O, Foran JM, Lister J, Schiller GJ, Wieduwilt MJ, Pagel JM, Stiff PJ, Liu D, Khan I, Stock W, Kambhampati S, Tallman MS, Morris L, Edwards J, Pusic I, Kantarjian HM, Mamelok R, Wong A, Van Syoc R, Kellerman L, Panuganti S, Mandalam R, Abboud CN, Ravandi F. PMID: 34156898; PMCID: PMC8500663.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCellsCTClinical Trials
    59. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021 08 07; 398(10299):491-502. Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Park JH, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Feng C, Dong J, Shen T, Milletti F, Rossi JM, Vezan R, Masouleh BK, Houot R. PMID: 34097852; PMCID: PMC11613962.
      View in: PubMed   Mentions: 289     Fields:    Translation:HumansCTClinical Trials
    60. Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States. Transplant Cell Ther. 2021 08; 27(8):679.e1-679.e8. Bhatt NS, Brazauskas R, Salit RB, Syrjala K, Bo-Subait S, Tecca H, Badawy SM, Baker KS, Beitinjaneh A, Bejanyan N, Byrne M, Dias A, Farhadfar N, Freytes CO, Ganguly S, Hashmi S, Hayashi RJ, Hong S, Inamoto Y, Jamani K, Kasow KA, Khera N, Krem MM, Lazarus HM, Lee CJ, Lee S, Majhail NS, Malone AK, Marks DI, Mau LW, Mayo SJ, Muffly LS, Nathan S, Nishihori T, Page KM, Preussler J, Rangarajan HG, Rotz SJ, Salooja N, Savani BN, Schears R, Schechter-Finkelstein T, Schiller G, Shah AJ, Sharma A, Wang T, Wirk B, Battiwalla M, Schoemans H, Hamilton B, Buchbinder D, Phelan R, Shaw B. PMID: 33895402; PMCID: PMC8425287.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    61. Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. Blood Adv. 2021 03 23; 5(6):1719-1728. Lin TL, Rizzieri DA, Ryan DH, Schiller GJ, Kolitz JE, Uy GL, Hogge DE, Solomon SR, Wieduwilt MJ, Ryan RJ, Faderl S, Cortes JE, Lancet JE. PMID: 33724305; PMCID: PMC7993093.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    62. Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma. EJHaem. 2021 Feb; 2(1):56-65. Gasparetto C, Lentzsch S, Schiller G, Callander N, Tuchman S, Chen C, White D, Kotb R, Sutherland H, Sebag M, Baljevic M, Bensinger W, LeBlanc R, Venner C, Bahlis N, Rossi A, Biran N, Sheehan H, Saint-Martin JR, Van Domelen D, Kai K, Shah J, Shacham S, Kauffman M, Lipe B. PMID: 35846104; PMCID: PMC9176052.
      View in: PubMed   Mentions: 17  
    63. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nat Med. 2020 12; 26(12):1852-1858. Burd A, Levine RL, Ruppert AS, Mims AS, Borate U, Stein EM, Patel P, Baer MR, Stock W, Deininger M, Blum W, Schiller G, Olin R, Litzow M, Foran J, Lin TL, Ball B, Boyiadzis M, Traer E, Odenike O, Arellano M, Walker A, Duong VH, Kovacsovics T, Collins R, Shoben AB, Heerema NA, Foster MC, Vergilio JA, Brennan T, Vietz C, Severson E, Miller M, Rosenberg L, Marcus S, Yocum A, Chen T, Stefanos M, Druker B, Byrd JC. PMID: 33106665; PMCID: PMC8530434.
      View in: PubMed   Mentions: 75     Fields:    Translation:HumansCTClinical Trials
    64. A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Clin Cancer Res. 2020 12 01; 26(23):6132-6140. Zeidan AM, Ridinger M, Lin TL, Becker PS, Schiller GJ, Patel PA, Spira AI, Tsai ML, Samuëlsz E, Silberman SL, Erlander M, Wang ES. PMID: 32998961.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    65. Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide. Leukemia. 2021 04; 35(4):1197-1202. Chowdhury O, O'Sullivan J, Barkas N, Wang G, Buck G, Hamblin A, Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, Kiladjian JJ, Mesa R, Passamonti F, Ribrag V, Schiller G, Vannucchi AM, Zhou D, McMullin MF, Zhong J, Gale RP, Mead AJ, RESUME trialists. PMID: 32770086; PMCID: PMC7610567.
      View in: PubMed   Mentions: 5     Fields:    
    66. Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment. Leukemia. 2020 12; 34(12):3286-3297. Siegel DS, Schiller GJ, Samaras C, Sebag M, Berdeja J, Ganguly S, Matous J, Song K, Seet CS, Talamo G, Acosta-Rivera M, Bar M, Quick D, Anz B, Fonseca G, Reece D, Pierceall WE, Chung W, Zafar F, Agarwal A, Bahlis NJ. PMID: 32376855; PMCID: PMC7685974.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
    67. A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. Blood Adv. 2020 04 28; 4(8):1656-1669. Schroeder MA, Khoury HJ, Jagasia M, Ali H, Schiller GJ, Staser K, Choi J, Gehrs L, Arbushites MC, Yan Y, Langmuir P, Srinivas N, Pratta M, Perales MA, Chen YB, Meyers G, DiPersio JF. PMID: 32324888; PMCID: PMC7189299.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCTClinical Trials
    68. Addressing the Measles-Mumps-Rubella Revaccination Guidelines for Allogenic Bone Marrow Transplant Patients: A Response to the American Society for Transplantation and Cellular Therapy 2019 Position Statement. Biol Blood Marrow Transplant. 2020 07; 26(7):e171-e172. Perez K, Shah VV, Schiller GJ. PMID: 32209395.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    69. Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia. Leuk Lymphoma. 2020 05; 61(5):1188-1194. Roboz GJ, Larson ML, Rubenstein SE, Solomon SR, Schiller GJ, An Q, Chiarella M, Louie AC, Lin TL. PMID: 32102577.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    70. Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen. Clin Lymphoma Myeloma Leuk. 2020 07; 20(7):468-479. Young PA, Gaut D, Kimaiyo DK, Grotts J, Romero T, Chute J, Schiller G, de Vos S, Eradat HA, Timmerman J. PMID: 32229199; PMCID: PMC7138188.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    71. Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience. Leuk Res. 2020 03; 90:106314. Gaut D, Burkenroad A, Duong T, Feammelli J, Sasine J, Schiller G. PMID: 32035355.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    72. Chronic myeloid leukemia stem cells require cell-autonomous pleiotrophin signaling. J Clin Invest. 2020 01 02; 130(1):315-328. Himburg HA, Roos M, Fang T, Zhang Y, Termini CM, Schlussel L, Kim M, Pang A, Kan J, Zhao L, Suh H, Sasine JP, Sapparapu G, Bowers PM, Schiller G, Chute JP. PMID: 31613796; PMCID: PMC6934217.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    73. How to address second and therapy-related acute myelogenous leukaemia. Br J Haematol. 2020 01; 188(1):116-128. Oliai C, Schiller G. PMID: 31863469.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    74. A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Cancers (Basel). 2019 Dec 26; 12(1). Uckun FM, Cogle CR, Lin TL, Qazi S, Trieu VN, Schiller G, Watts JM. PMID: 31888052; PMCID: PMC7016810.
      View in: PubMed   Mentions: 16  
    75. Disease characteristics of diffuse large B-cell lymphoma predicting relapse and survival after autologous stem cell transplantation: A single institution experience. Hematol Oncol. 2020 Feb; 38(1):38-50. Gaut D, Romero T, Oveisi D, Howell G, Schiller G. PMID: 31674036.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    76. Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure. Br J Haematol. 2020 02; 188(4):501-510. Siegel DS, Schiller GJ, Song KW, Agajanian R, Stockerl-Goldstein K, Kaya H, Sebag M, Samaras C, Malek E, Talamo G, Seet CS, Mouro J, Pierceall WE, Zafar F, Chung W, Srinivasan S, Agarwal A, Bahlis NJ. PMID: 31588567; PMCID: PMC7027539.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    77. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. N Engl J Med. 2019 08 22; 381(8):727-738. Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S. PMID: 31433920.
      View in: PubMed   Mentions: 267     Fields:    Translation:HumansCTClinical Trials
    78. Identifying risk factors associated with worse outcomes in adolescents and young adults undergoing hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2019 12; 66(12):e27940. Friend BD, Tang K, Markovic D, Elashoff D, Moore TB, Schiller GJ. PMID: 31429528.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    79. Autoimmune hemolytic anemia in refractory hairy cell leukemia on dabrafenib and trametinib. Ann Hematol. 2019 Oct; 98(10):2443-2445. Ng DB, Schiller G, Ha E. PMID: 31410508.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    80. B-cell acute lymphoblastic leukemia as a secondary malignancy following diffuse large B-cell lymphoma. Hematol Rep. 2019 May 23; 11(2):8100. Gaut D, Bejjani A, Sasine J, Schiller G. PMID: 31285810; PMCID: PMC6589539.
      View in: PubMed   Mentions:
    81. Cardiac Complications in the Adult Bone Marrow Transplant Patient. Curr Oncol Rep. 2019 03 02; 21(3):28. Tuzovic M, Mead M, Young PA, Schiller G, Yang EH. PMID: 30826891.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    82. Hematopoietic stem cell transplantation in primary central nervous system lymphoma: a review of the literature. Int J Hematol. 2019 Mar; 109(3):260-277. Gaut D, Schiller GJ. PMID: 30671909.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    83. Liposomal Cytarabine-Daunorubicin (CPX-351) Extravasation: Case Report and Literature Review. Anticancer Res. 2018 Dec; 38(12):6927-6930. Howell G, Oliai C, Schiller G. PMID: 30504411.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    84. Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia. Curr Treat Options Oncol. 2018 10 25; 19(12):63. Levin-Epstein R, Oliai C, Schiller G. PMID: 30362051.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    85. High-Dose Vincristine Sulfate Liposome Injection, for Advanced, Relapsed, or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in an Adolescent and Young Adult Subgroup of a Phase 2 Clinical Trial. J Adolesc Young Adult Oncol. 2018 10; 7(5):546-552. Schiller GJ, Damon LE, Coutre SE, Hsu P, Bhat G, Douer D. PMID: 30239252.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCellsCTClinical Trials
    86. Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors. Ann Hematol. 2019 Jan; 98(1):159-167. Stein AS, Schiller G, Benjamin R, Jia C, Zhang A, Zhu M, Zimmerman Z, Topp MS. PMID: 30238148; PMCID: PMC6334725.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCTClinical Trials
    87. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia. 2018 08; 32(8):1768-1777. Kreitman RJ, Dearden C, Zinzani PL, Delgado J, Karlin L, Robak T, Gladstone DE, le Coutre P, Dietrich S, Gotic M, Larratt L, Offner F, Schiller G, Swords R, Bacon L, Bocchia M, Bouabdallah K, Breems DA, Cortelezzi A, Dinner S, Doubek M, Gjertsen BT, Gobbi M, Hellmann A, Lepretre S, Maloisel F, Ravandi F, Rousselot P, Rummel M, Siddiqi T, Tadmor T, Troussard X, Yi CA, Saglio G, Roboz GJ, Balic K, Standifer N, He P, Marshall S, Wilson W, Pastan I, Yao NS, Giles F. PMID: 30030507; PMCID: PMC6087717.
      View in: PubMed   Mentions: 99     Fields:    Translation:Humans
    88. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. 2018 09 10; 36(26):2684-2692. Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, Medeiros BC. PMID: 30024784; PMCID: PMC6127025.
      View in: PubMed   Mentions: 364     Fields:    Translation:HumansCTClinical Trials
    89. Response. Biol Blood Marrow Transplant. 2018 09; 24(9):1953-1954. Molina A, Winston DJ, Pan D, Schiller GJ. PMID: 29909155.
      View in: PubMed   Mentions:    Fields:    
    90. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. Blood. 2018 08 09; 132(6):598-607. Cortes JE, Tallman MS, Schiller GJ, Trone D, Gammon G, Goldberg SL, Perl AE, Marie JP, Martinelli G, Kantarjian HM, Levis MJ. PMID: 29875101; PMCID: PMC6085992.
      View in: PubMed   Mentions: 81     Fields:    Translation:HumansCellsCTClinical Trials
    91. Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica. 2018 11; 103(11):e514-e518. Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Pigneux A, Horst HA, Récher C, Klimek VM, Cortes JE, Carella AM, Egyed M, Krug U, Fox JA, Craig AR, Ward R, Smith JA, Acton G, Kantarjian HM, Stuart RK. PMID: 29794146; PMCID: PMC6278965.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    92. The Slippery Slope of Legalization of Physician-Assisted Suicide. Ann Intern Med. 2018 05 01; 168(9):683. Schiller G. PMID: 29710259.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    93. Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia. N Engl J Med. 2018 04 19; 378(16):1479-1493. Thompson AA, Walters MC, Kwiatkowski J, Rasko JEJ, Ribeil JA, Hongeng S, Magrin E, Schiller GJ, Payen E, Semeraro M, Moshous D, Lefrere F, Puy H, Bourget P, Magnani A, Caccavelli L, Diana JS, Suarez F, Monpoux F, Brousse V, Poirot C, Brouzes C, Meritet JF, Pondarré C, Beuzard Y, Chrétien S, Lefebvre T, Teachey DT, Anurathapan U, Ho PJ, von Kalle C, Kletzel M, Vichinsky E, Soni S, Veres G, Negre O, Ross RW, Davidson D, Petrusich A, Sandler L, Asmal M, Hermine O, De Montalembert M, Hacein-Bey-Abina S, Blanche S, Leboulch P, Cavazzana M. PMID: 29669226.
      View in: PubMed   Mentions: 281     Fields:    Translation:HumansCellsCTClinical Trials
    94. Secondary clonal hematologic neoplasia following successful therapy for acute promyelocytic leukemia (APL): A report of two cases and review of the literature. Leuk Res Rep. 2018; 9:65-71. Gaut D, Sasine J, Schiller G. PMID: 29892552; PMCID: PMC5993360.
      View in: PubMed   Mentions: 3  
    95. Increased Incidence of Nocardial Infections in an Era of Atovaquone Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Biol Blood Marrow Transplant. 2018 08; 24(8):1715-1720. Molina A, Winston DJ, Pan D, Schiller GJ. PMID: 29555315.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    96. Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma. Cardiooncology. 2018; 4:2. Yang EH, Courtney C, Garg V, Fradley MG, Schiller GJ. PMID: 32154003; PMCID: PMC7048019.
      View in: PubMed   Mentions: 2  
    97. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2018 03 20; 36(9):859-866. Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, Zonder J, Baz R, Nooka A, Richter J, Cole C, Vij R, Jakubowiak A, Abonour R, Schiller G, Parker TL, Costa LJ, Kaminetzky D, Hoffman JE, Yee AJ, Chari A, Siegel D, Fonseca R, Van Wier S, Ahmann G, Lopez I, Kauffman M, Shacham S, Saint-Martin JR, Picklesimer CD, Choe-Juliak C, Stewart AK. PMID: 29381435; PMCID: PMC6905485.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansCTClinical Trials
    98. Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation. Biol Blood Marrow Transplant. 2018 05; 24(5):945-955. Bejanyan N, Zhang MJ, Wang HL, Lazaryan A, de Lima M, Marks DI, Sandmaier BM, Bachanova V, Rowe J, Tallman M, Kebriaei P, Kharfan-Dabaja M, Peter Gale R, Lazarus HM, Ustun C, Copelan E, Ky Hamilton B, Schiller G, Hogan W, Hashmi S, Seftel M, Kanakry CG, Olsson RF, Martino R, Saber W, Khoury HJ, Weisdorf DJ. PMID: 29275139; PMCID: PMC5953798.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    99. Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment. Cancer Chemother Pharmacol. 2018 01; 81(1):171-178. Nikanjam M, Capparelli EV, Lancet JE, Louie A, Schiller G. PMID: 29167924; PMCID: PMC5756117.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    100. Closing the gap: Novel therapies in treating acute lymphoblastic leukemia in adolescents and young adults. Blood Rev. 2018 03; 32(2):122-129. Friend BD, Schiller GJ. PMID: 28969872.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    101. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017 08; 18(8):1061-1075. Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, Röllig C, Neubauer A, Martinelli G, Bahceci E, Levis M. PMID: 28645776; PMCID: PMC5572576.
      View in: PubMed   Mentions: 250     Fields:    Translation:HumansCellsCTClinical Trials
    102. Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant. 2017 May; 23(5):853-856. Hamadani M, Kanate AS, DiGilio A, Ahn KW, Smith SM, Lee JW, Ayala E, Chao N, Hari P, Bolaños-Meade J, Gress R, Smedegaard Anderson N, Chen YB, Farooq U, Schiller G, Yared J, Sureda A, Fenske TS, Olteanu H. PMID: 28161608; PMCID: PMC5410937.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    103. Novel Cytogenetic Findings in a Case of Mixed Phenotype Acute Leukemia within the Context of a Complex Karyotype. J Assoc Genet Technol. 2017; 43(1):20-22. Shabsovich D, Schiller G, Naeini Y, Collins R, Tirado CA. PMID: 28459703.
      View in: PubMed   Mentions: 1  
    104. Acute Myeloid Leukemia: How Do We Measure Success? Curr Hematol Malig Rep. 2016 12; 11(6):528-536. Sasine JP, Schiller GJ. PMID: 27604228.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    105. A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia. Cancer Med. 2016 11; 5(11):3031-3040. Reed GA, Schiller GJ, Kambhampati S, Tallman MS, Douer D, Minden MD, Yee KW, Gupta V, Brandwein J, Jitkova Y, Gronda M, Hurren R, Shamas-Din A, Schuh AC, Schimmer AD. PMID: 27734609; PMCID: PMC5119957.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCellsCTClinical Trials
    106. A novel three-way rearrangement involving ETV6 (12p13) and ABL1 (9q34) with an unknown partner on 3p25 resulting in a possible ETV6-ABL1 fusion in a patient with acute myeloid leukemia: a case report and a review of the literature. Biomark Res. 2016; 4(1):16. Tirado CA, Siangchin K, Shabsovich DS, Sharifian M, Schiller G. PMID: 27570624; PMCID: PMC5000511.
      View in: PubMed   Mentions: 12  
    107. Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2016 Dec 01; 22(23):5688-5695. Raje NS, Faber EA, Richardson PG, Schiller G, Hohl RJ, Cohen AD, Forero A, Carpenter S, Nguyen TS, Conti I, Kaiser CJ, Cronier DM, Wooldridge JE, Anderson KC. PMID: 27287072.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCellsCTClinical Trials
    108. Preventive strategies for invasive Aspergillus in acute myelogenous leukemia. Clin Adv Hematol Oncol. 2016 May; 14(5):324-5. Schiller G. PMID: 27379692.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    109. Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD-Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-Transplantation. Biol Blood Marrow Transplant. 2016 06; 22(6):982-990. Schiller GJ, Tuttle P, Desai P. PMID: 26785334.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    110. High-Intensity Induction in the Elderly. Acta Haematol. 2016; 135(1):53-4. Schiller GJ. PMID: 26444244.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    111. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015 Sep; 16(9):1025-1036. Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst HA, Recher C, Klimek VM, Cortes J, Roboz GJ, Odenike O, Thomas X, Havelange V, Maertens J, Derigs HG, Heuser M, Damon L, Powell BL, Gaidano G, Carella AM, Wei A, Hogge D, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Stuart RK, Kantarjian HM. PMID: 26234174; PMCID: PMC4822512.
      View in: PubMed   Mentions: 69     Fields:    Translation:HumansCTClinical Trials
    112. New cancers after autotransplantations for multiple myeloma. Biol Blood Marrow Transplant. 2015 Apr; 21(4):738-45. Mahindra A, Raval G, Mehta P, Brazauskas R, Zhang MJ, Zhong X, Bird JM, Freytes CO, Hale GA, Herzig R, Holmberg LA, Kamble RT, Kumar S, Lazarus HM, Majhail NS, Marks DI, Moreb JS, Olsson R, Saber W, Savani BN, Schiller GJ, Tay J, Vogl DT, Waller EK, Wiernik PH, Wirk B, Lonial S, Krishnan AY, Dispenzieri A, Brandenburg NA, Gale RP, Hari PN. PMID: 25555448; PMCID: PMC4359647.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    113. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015 Jan; 16(1):57-66. Topp MS, Gökbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, Dombret H, Fielding AK, Heffner L, Larson RA, Neumann S, Foà R, Litzow M, Ribera JM, Rambaldi A, Schiller G, Brüggemann M, Horst HA, Holland C, Jia C, Maniar T, Huber B, Nagorsen D, Forman SJ, Kantarjian HM. PMID: 25524800.
      View in: PubMed   Mentions: 540     Fields:    Translation:HumansCTClinical Trials
    114. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer. 2015 Jan 15; 121(2):234-42. Cortes JE, Goldberg SL, Feldman EJ, Rizzeri DA, Hogge DE, Larson M, Pigneux A, Recher C, Schiller G, Warzocha K, Kantarjian H, Louie AC, Kolitz JE. PMID: 25223583; PMCID: PMC5542857.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCTClinical Trials
    115. Emerging strategies for high-risk and relapsed/refractory acute myeloid leukemia: novel agents and approaches currently in clinical trials. Blood Rev. 2015 Jan; 29(1):1-9. Sasine JP, Schiller GJ. PMID: 25441922.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimals
    116. An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes. Leuk Res Rep. 2014; 3(2):58-61. Goldberg SL, Fenaux P, Craig MD, Gyan E, Lister J, Kassis J, Pigneux A, Schiller GJ, Jung J, Jane Leonard E, Fingert H, Westervelt P. PMID: 25068104; PMCID: PMC4110881.
      View in: PubMed   Mentions: 50  
    117. Evolving treatment strategies in patients with high-risk acute myeloid leukemia. Leuk Lymphoma. 2014 Nov; 55(11):2438-48. Schiller GJ. PMID: 24432896.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    118. Allogeneic transplantation as therapy for acute myelogenous leukemia in the elderly. Biol Blood Marrow Transplant. 2014 Apr; 20(4):437-8. Schiller GJ. PMID: 24487045.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    119. Myelodysplasia. Hematology. 2013 Sep; 18(5):307-8. Schiller GJ, Reese N. PMID: 24020490.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    120. High-dose cytarabine (HD araC) in the treatment of leukemias: a review. Curr Hematol Malig Rep. 2013 Jun; 8(2):141-8. Reese ND, Schiller GJ. PMID: 23666364.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    121. Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant. 2013 May; 19(5):760-6. Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT, Kumar S, Lill M, Meehan KR, Saber W, Schriber J, Tay J, Vogl DT, Wirk B, Savani BN, Gale RP, Vesole DH, Schiller GJ, Abidi M, Anderson KC, Nishihori T, Kalaycio ME, Vose JM, Moreb JS, Drobyski W, Munker R, Roy V, Ghobadi A, Holland HK, Nath R, To LB, Maiolino A, Kassim AA, Giralt SA, Landau H, Schouten HC, Maziarz RT, Mikhael J, Kindwall-Keller T, Stiff PJ, Gibson J, Lonial S, Krishnan A, Dispenzieri A, Hari P, Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant . PMID: 23298856; PMCID: PMC3816739.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    122. High-risk acute myelogenous leukemia: treatment today ... and tomorrow. Hematology Am Soc Hematol Educ Program. 2013; 2013:201-8. Schiller GJ. PMID: 24319182.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    123. Treatment of adults with acute lymphoblastic leukemia: do the specifics of the regimen matter?: Results from a prospective randomized trial. Cancer. 2013 Mar 15; 119(6):1186-94. Lamanna N, Heffner LT, Kalaycio M, Schiller G, Coutre S, Moore J, Seiter K, Maslak P, Panageas K, Golde D, Weiss MA. PMID: 23280086.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    124. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol. 2013 Feb 20; 31(6):676-83. O'Brien S, Schiller G, Lister J, Damon L, Goldberg S, Aulitzky W, Ben-Yehuda D, Stock W, Coutre S, Douer D, Heffner LT, Larson M, Seiter K, Smith S, Assouline S, Kuriakose P, Maness L, Nagler A, Rowe J, Schaich M, Shpilberg O, Yee K, Schmieder G, Silverman JA, Thomas D, Deitcher SR, Kantarjian H. PMID: 23169518; PMCID: PMC4979201.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCellsCTClinical Trials
    125. Secondary hemophagocytic lymphohistiocytosis in adults: an update on diagnosis and therapy. Clin Adv Hematol Oncol. 2012 Nov; 10(11):726-32. Kleynberg RL, Schiller GJ. PMID: 23271259.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    126. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol. 2012 Nov; 13(11):1096-104. Kantarjian H, Faderl S, Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Claxton D, Goldberg SL, Arellano M, Strickland SA, Seiter K, Schiller G, Jabbour E, Chiao J, Plunkett W. PMID: 23075701; PMCID: PMC4004358.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    127. Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012 Oct; 12(5):319-24. Weber DM, Graef T, Hussein M, Sobecks RM, Schiller GJ, Lupinacci L, Hardwick JS, Jagannath S. PMID: 23040438.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    128. Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research. Haematologica. 2013 Feb; 98(2):185-92. Keating A, DaSilva G, Pérez WS, Gupta V, Cutler CS, Ballen KK, Cairo MS, Camitta BM, Champlin RE, Gajewski JL, Lazarus HM, Lill M, Marks DI, Nabhan C, Schiller GJ, Socie G, Szer J, Tallman MS, Weisdorf DJ. PMID: 22983587; PMCID: PMC3561424.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    129. Minimal residual disease as a predictive factor for relapse after allogeneic hematopoietic stem cell transplant in adult patients with acute myeloid leukemia in first and second complete remission. Cancers (Basel). 2012 Jun 20; 4(2):601-17. Grubovikj RM, Alavi A, Koppel A, Territo M, Schiller GJ. PMID: 24213327; PMCID: PMC3712693.
      View in: PubMed   Mentions: 10  
    130. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 2012 Jul; 13(7):696-706. Pettengell R, Coiffier B, Narayanan G, de Mendoza FH, Digumarti R, Gomez H, Zinzani PL, Schiller G, Rizzieri D, Boland G, Cernohous P, Wang L, Kuepfer C, Gorbatchevsky I, Singer JW. PMID: 22652183.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    131. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. J Clin Oncol. 2012 Jul 10; 30(20):2492-9. Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM. PMID: 22585697; PMCID: PMC4874149.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansCTClinical Trials
    132. Blastic plasmacytoid dendritic cell neoplasm. Clin Adv Hematol Oncol. 2012 Jan; 10(1):60-2. Lee JK, Schiller G. PMID: 22398811.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    133. Transplantation for congenital bone marrow failure syndromes. Bone Marrow Res. 2011; 2011:849387. Morimoto K, Moore TB, Schiller G, Sakamoto KM. PMID: 22046571; PMCID: PMC3199936.
      View in: PubMed   Mentions: 1  
    134. When a gold standard is made of tin. Blood. 2010 Nov 25; 116(22):4386-7. Schiller GJ. PMID: 21109621.
      View in: PubMed   Mentions: 2     Fields:    
    135. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol. 2010 Oct 01; 28(28):4339-45. Fischer T, Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C, Fox E, Ehninger G, Feldman EJ, Schiller GJ, Klimek VM, Nimer SD, Gilliland DG, Dutreix C, Huntsman-Labed A, Virkus J, Giles FJ. PMID: 20733134; PMCID: PMC4135183.
      View in: PubMed   Mentions: 227     Fields:    Translation:HumansCTClinical Trials
    136. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study. J Clin Oncol. 2010 Sep 20; 28(27):4207-13. Cortes J, Moore JO, Maziarz RT, Wetzler M, Craig M, Matous J, Luger S, Dey BR, Schiller GJ, Pham D, Abboud CN, Krishnamurthy M, Brown A, Laadem A, Seiter K. PMID: 20713865; PMCID: PMC4979236.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCTClinical Trials
    137. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010 Aug 10; 28(23):3730-8. Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM, Kamble R, Copelan E, de Lima M, Gupta V, Keating A, Lazarus HM, Litzow MR, Marks DI, Maziarz RT, Rizzieri DA, Schiller G, Schultz KR, Tallman MS, Weisdorf D. PMID: 20625136; PMCID: PMC2917308.
      View in: PubMed   Mentions: 171     Fields:    Translation:HumansCTClinical Trials
    138. Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2011 Apr; 17(4):507-15. Winston DJ, Bartoni K, Territo MC, Schiller GJ. PMID: 20460163.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    139. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2010 Feb 01; 28(4):556-61. Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. PMID: 20026803.
      View in: PubMed   Mentions: 199     Fields:    Translation:HumansCTClinical Trials
    140. Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia. J Clin Oncol. 2010 Feb 10; 28(5):815-21. Schiller GJ, O'Brien SM, Pigneux A, Deangelo DJ, Vey N, Kell J, Solomon S, Stuart RK, Karsten V, Cahill AL, Albitar MX, Giles FJ. PMID: 20026800.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    141. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant. 2010 Mar; 16(3):358-67. Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ, Cervantes F, Devine SM, Gale RP, Gupta V, Hahn TE, Hogan WJ, Kröger N, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Schiller G, Schouten HC, Roy V, Wiernik PH, Horowitz MM, Giralt SA, Arora M. PMID: 19879949; PMCID: PMC2908949.
      View in: PubMed   Mentions: 101     Fields:    
    142. Current status of acute myeloid leukemia treatment in the elderly. Clin Adv Hematol Oncol. 2009 Sep; 7(9):580-2. Schiller G. PMID: 20020668.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    143. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol. 2009 Oct 01; 27(28):4741-6. Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Hedley DW, Brandwein J, Xu W, Mak DH, LaCasse E, Jacob C, Morris SJ, Jolivet J, Andreeff M. PMID: 19652057; PMCID: PMC5073380.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCTClinical Trials
    144. Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. Leuk Lymphoma. 2009 Apr; 50(4):559-65. Chanan-Khan AA, Niesvizky R, Hohl RJ, Zimmerman TM, Christiansen NP, Schiller GJ, Callander N, Lister J, Oken M, Jagannath S. PMID: 19373653.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    145. Myelodysplastic syndrome: An update on diagnosis and therapy. Curr Hematol Malig Rep. 2009 Jan; 4(1):10-6. Koppel A, Schiller G. PMID: 20425433.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    146. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood. 2009 Mar 26; 113(13):3110-8. Ringdén O, Pavletic SZ, Anasetti C, Barrett AJ, Wang T, Wang D, Antin JH, Di Bartolomeo P, Bolwell BJ, Bredeson C, Cairo MS, Gale RP, Gupta V, Hahn T, Hale GA, Halter J, Jagasia M, Litzow MR, Locatelli F, Marks DI, McCarthy PL, Cowan MJ, Petersdorf EW, Russell JA, Schiller GJ, Schouten H, Spellman S, Verdonck LF, Wingard JR, Horowitz MM, Arora M. PMID: 19059878; PMCID: PMC2662650.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    147. Comparison of twin and autologous transplants for multiple myeloma. Biol Blood Marrow Transplant. 2008 Oct; 14(10):1118-1124. Bashey A, Pérez WS, Zhang MJ, Anderson KC, Ballen K, Berenson JR, To LB, Fonseca R, Freytes CO, Gale RP, Gibson J, Giralt SA, Kyle RA, Lazarus HM, Maharaj D, McCarthy PL, Milone GA, Nimer S, Pavlovsky S, Reece DE, Schiller G, Vesole DH, Hari P, Plasma Cell Disorders Working Committee. PMID: 18804041; PMCID: PMC2584240.
      View in: PubMed   Mentions: 12     Fields:    Translation:CTClinical Trials
    148. Myelodysplastic syndrome: an update on diagnosis and therapy. Curr Oncol Rep. 2008 Sep; 10(5):372-8. Koppel A, Schiller G. PMID: 18706264.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    149. Acute myeloid leukemia in the elderly: conventional and novel treatment approaches. Blood Rev. 2008 Jul; 22(4):221-34. Craig CM, Schiller GJ. PMID: 18433953.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    150. Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood. 2008 Jul 15; 112(2):426-34. Marks DI, Pérez WS, He W, Zhang MJ, Bishop MR, Bolwell BJ, Bredeson CN, Copelan EA, Gale RP, Gupta V, Hale GA, Isola LM, Jakubowski AA, Keating A, Klumpp TR, Lazarus HM, Liesveld JL, Maziarz RT, McCarthy PL, Sabloff M, Schiller G, Sierra J, Tallman MS, Waller EK, Wiernik PH, Weisdorf DJ. PMID: 18398065; PMCID: PMC2442751.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    151. Standardized protocol to identify high-risk patients undergoing therapeutic apheresis procedures. J Clin Apher. 2008; 23(3):111-5. Lu Q, Nedelcu E, Ziman A, Bumerts P, Fernando L, Schiller G. PMID: 18521857.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    152. Exclusive use of acid citrate dextrose for anticoagulation during extracorporeal photopheresis in patients with contraindications to heparin: an effective protocol. J Clin Apher. 2008; 23(2):66-73. Nedelcu E, Ziman A, Fernando LP, Cook K, Bumerts P, Schiller G. PMID: 18286495.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    153. Conjugation of an anti transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells. Mol Cancer Ther. 2007 Nov; 6(11):2995-3008. Daniels TR, Ng PP, Delgado T, Lynch MR, Schiller G, Helguera G, Penichet ML. PMID: 18025284.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    154. Duodenal lymphoma: a rare and morbid tumor. Am Surg. 2007 Oct; 73(10):1057-62. Chestovich PJ, Schiller G, Sasu S, Hiatt JR. PMID: 17983081.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    155. Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor. Blood. 2006 Oct 15; 108(8):2745-54. Ng PP, Helguera G, Daniels TR, Lomas SZ, Rodriguez JA, Schiller G, Bonavida B, Morrison SL, Penichet ML. PMID: 16804109; PMCID: PMC1895578.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    156. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis. 2006 Jun 15; 42(12):1726-34. Raad II, Graybill JR, Bustamante AB, Cornely OA, Gaona-Flores V, Afif C, Graham DR, Greenberg RN, Hadley S, Langston A, Negroni R, Perfect JR, Pitisuttithum P, Restrepo A, Schiller G, Pedicone L, Ullmann AJ. PMID: 16705579.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    157. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol. 2006 Jun 01; 24(16):2456-64. Schiller GJ, Slack J, Hainsworth JD, Mason J, Saleh M, Rizzieri D, Douer D, List AF. PMID: 16651647.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    158. Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients > or =60 years with acute myelogenous leukemia. Biol Blood Marrow Transplant. 2006 Apr; 12(4):466-71. Lashkari A, Lowe T, Collisson E, Paquette R, Emmanouilides C, Territo M, Schiller G. PMID: 16545730.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    159. Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant. 2006 Feb; 12(2):204-16. Tallman MS, Pérez WS, Lazarus HM, Gale RP, Maziarz RT, Rowe JM, Marks DI, Cahn JY, Bashey A, Bishop MR, Christiansen N, Frankel SR, García JJ, Ilhan O, Laughlin MJ, Liesveld J, Linker C, Litzow MR, Luger S, McCarthy PL, Milone GA, Pavlovsky S, Phillips GL, Russell JA, Saez RA, Schiller G, Sierra J, Weiner RS, Zander AR, Zhang MJ, Keating A, Weisdorf DJ, Horowitz MM. PMID: 16443518.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    160. Myelodysplasic syndromes: a comprehensive review. Blood Rev. 2005 Nov; 19(6):301-19. Catenacci DV, Schiller GJ. PMID: 15885860.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    161. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood. 2006 Jan 01; 107(1):293-300. Heidel F, Solem FK, Breitenbuecher F, Lipka DB, Kasper S, Thiede MH, Brandts C, Serve H, Roesel J, Giles F, Feldman E, Ehninger G, Schiller GJ, Nimer S, Stone RM, Wang Y, Kindler T, Cohen PS, Huber C, Fischer T. PMID: 16150941.
      View in: PubMed   Mentions: 122     Fields:    Translation:HumansCells
    162. The evolution of antibodies into versatile tumor-targeting agents. Clin Cancer Res. 2005 Jan 01; 11(1):129-38. Lin MZ, Teitell MA, Schiller GJ. PMID: 15671537.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    163. Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). Blood. 2005 Jan 01; 105(1):335-40. Kindler T, Breitenbuecher F, Kasper S, Estey E, Giles F, Feldman E, Ehninger G, Schiller G, Klimek V, Nimer SD, Gratwohl A, Choudhary CR, Mueller-Tidow C, Serve H, Gschaidmeier H, Cohen PS, Huber C, Fischer T. PMID: 15345593.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansAnimalsCells
    164. Elimination of Aspergillus infection in allogeneic stem cell transplant recipients with long-term itraconazole prophylaxis: prevention is better than treatment. Blood. 2004 Sep 01; 104(5):1581; author reply 1582. Winston DJ, Emmanouilides C, Bartoni K, Schiller GJ, Paquette R, Territo MC. PMID: 15317732.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    165. Re: allogenic transplantation after nonmyelosuppressive conditioning--the effect of single-agent pentostatin. Biol Blood Marrow Transplant. 2004 Aug; 10(8):576-7. Schiller GJ, Malone R, Figlin R. PMID: 15328623.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    166. Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma. Clin Lymphoma. 2004 Jun; 5(1):45-9. Emmanouilides C, Colovos C, Pinter-Brown L, Hernandez L, Schiller G, Territo M, Rosen P. PMID: 15245607.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    167. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood. 2003 Apr 01; 101(7):2476-82. Levine JE, Harris RE, Loberiza FR, Armitage JO, Vose JM, Van Besien K, Lazarus HM, Horowitz MM, Bashey A, Bolwell BJ, Burns LJ, Cairo MS, Champlin RE, Freytes CO, Gibson J, Goldstein SC, Laughlin MJ, Lister J, Marks DI, Maziarz RT, Miller AM, Milone GA, Pavlovsky S, Pecora AL, Rizzo JD, Schiller G, Schouten HC, Zhang MJ, Lymphoma Study Writing Committee, International Bone Marrow Transplant Registry and Autologous Blood. PMID: 12456505.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    168. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003 Apr 01; 101(7):2461-3. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. PMID: 12433676.
      View in: PubMed   Mentions: 380     Fields:    Translation:HumansCells
    169. Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin Infect Dis. 2002 Jun 15; 34(12):1648-50. Mellinghoff IK, Winston DJ, Mukwaya G, Schiller GJ. PMID: 12032903.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimals
    Gary's Networks
    Concepts (428)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (62)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-15-g9ae42700 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California